Dupixent (dupilumab) prior authorization
Customize your policy alerts
Sign up for all careoregon policy alerts
Know when careoregon releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization criteria and reauthorization requirements for Dupixent (dupilumab) for multiple diagnoses including allergic fungal rhinosinusitis, atopic dermatitis, asthma, bullous pemphigoid, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria for CareOregon members.
No material clinical or coverage changes in this revision.
Coverage Criteria by Indication
AFRS Initial Authorization
Covered when ALL of the following are met for Allergic Fungal Rhinosinusitis (initial authorization):
AFRS Reauthorization
AFRS reauthorization criteria:
Atopic Dermatitis Initial Authorization
Atopic dermatitis initial authorization criteria (pediatric and adult pathways):
Atopic Dermatitis Reauthorization
Atopic dermatitis reauthorization criteria:
Asthma Initial Authorization
Asthma initial authorization criteria:
Asthma Reauthorization
Asthma reauthorization criteria:
Bullous Pemphigoid Initial Authorization
Bullous pemphigoid initial authorization criteria:
Bullous Pemphigoid Reauthorization
Bullous pemphigoid reauthorization criteria:
CRSwNP Initial Authorization
Chronic rhinosinusitis with nasal polyps initial authorization criteria:
CRSwNP Reauthorization
CRSwNP reauthorization criteria:
Chronic Spontaneous Urticaria Initial Authorization
Chronic spontaneous urticaria initial authorization criteria:
Chronic Spontaneous Urticaria Reauthorization
Chronic spontaneous urticaria reauthorization criteria:
Chronic Spontaneous Urticaria — Initial Authorization
Covered when ALL of the following are met
Approval length: 6 months for initial authorization
Chronic Spontaneous Urticaria — Reauthorization
Covered when ALL of the following are met
Approval length: 12 months for reauthorization
COPD with Chronic Bronchitis — Reauthorization
Covered when ALL of the following are met
Approval length: 12 months for reauthorization
Eosinophilic Esophagitis — Initial and Reauthorization
Covered when ALL of the following are met
Initial approval length 6 months; reauthorization 12 months
Prurigo Nodularis — Initial and Reauthorization
Covered when ALL of the following are met (criteria differ by age group)
Initial approval length 6 months for PN
Reauthorization approval length 12 months
This section summarizes the coverage criteria for Chronic Spontaneous Urticaria (CSU)≥ 6 weeks, that disease is severe (for example, ≥50 wheals or large confluent wheals and pruritus that impacts sleep or daily activities), and that the request is prescribed by or in consultation with an allergist/immunologist or otolaryngologist. The member must be at least 12 years of age to meet initial authorization criteria.
Prior therapy requirements must be clearly documented. For CSU initial approval, the member must have failed all of the following: two second‑generation antihistamines, an antihistamine at a higher‑than‑normal dose (e.g., cetirizine 20 mg daily), montelukast, either hydroxyzine or an H2 antagonist (such as famotidine or cimetidine), and prior trial of omalizumab (Xolair) with pre‑approval. Reauthorization requires documentation of significant clinical improvement (for example, decreased wheals/angioedema or improved sleep/ability to participate) and a provider statement that continued therapy is medically necessary and tapering/stopping is not appropriate.
Approval lengths are indication‑specific: initial authorization for CSU is typically 6 months, and reauthorization approval length is typically 12 months. Requests should include objective documentation of prior therapy trials, disease duration, severity measures, and specialist involvement to support medical necessity.
No additional exclusions or not‑medically‑necessary (NMN) conditions are listed in the provided CSU excerpt. Reviewers should rely on the explicit criteria above; absence of required documentation (for example, missing prior therapy trials or lack of documentation of ≥6 weeks of disease) may lead to denial.
Initial Therapy Requirements
Initial therapy
Initial authorization criteria vary by indication and require specialist involvement, diagnostic confirmation, and prior therapy failures as detailed per indication.
Initial therapy requirements
Initial authorization criteria per indication
Reauthorization / Continuation Requirements
Reauthorization requirements
Reauthorization generally requires documented clinical improvement and provider attestation that continued therapy is medically necessary and tapering is not appropriate.
Continuation/Reauthorization criteria
Reauthorization requires documented clinical benefit and provider statement that continued therapy is medically necessary and not appropriate to stop
Required Prior Therapy Trials
| Indication / Step | Required prior trials or criteria |
|---|---|
| Allergic Fungal Rhinosinusitis (AFRS) | |
| Failure of (or contraindication to) two intranasal corticosteroids (e.g., fluticasone, budesonide); plus CT-confirmed AFRS with two supporting findings and history of sinonasal surgery required per AFRS criteria | |
| Atopic Dermatitis (moderate-to-severe) | |
| Failure of combination steroid and nonsteroid topical medications; OR failure of two of the following: combination topical therapy, an oral DMARD (e.g., methotrexate or cyclosporine), or phototherapy | |
| Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) | |
| Failure of at least 2 prior intranasal corticosteroids and Sinuva; member must be adherent to a nasal corticosteroid and have recurrent polyps after multiple sinus surgeries (prescribed by allergist or ENT) | |
| Other indications (select dermatologic, pulmonary, GI conditions) | |
| Initial authorization criteria vary by indication but generally require specialist prescriber, diagnostic confirmation where applicable, and documented failure of listed prior therapies (see indication-specific criteria) |
| CSU Step | Required prior therapies (must try and fail) |
|---|---|
| Ordered sequence required before Dupixent for chronic spontaneous urticaria (CSU) | |
| Failure of ALL of the following: at least two second‑generation antihistamines (e.g., loratadine, cetirizine); an antihistamine at higher-than-normal dose (e.g., cetirizine 20 mg daily); montelukast; either hydroxyzine or an H2 antagonist (e.g., famotidine or cimetidine); and prior trial of Xolair (omalizumab) with pre-approval |
Clinical Thresholds and Key Values
What Providers Must Do
Prior authorization required; typical approval lengths
Prior authorization is required for Dupixent. Initial approvals are typically 6 months for many indications; reauthorization approval lengths are generally 12 months for certain diagnoses.
Specialist prescriber required for specific indications
Certain indications require that Dupixent be prescribed by a relevant specialist (examples in the policy include allergist/immunologist, ENT, pulmonologist, dermatologist, or gastroenterologist).
PA required for Dupixent in chronic spontaneous urticaria (CSU)
Prior authorization is required for Dupixent for chronic spontaneous urticaria (CSU); initial approval requires meeting CSU clinical criteria and specialist involvement, and reauthorization requires documented significant improvement.
- Initial approval length: 6 months
- Reauthorization approval length: 12 months
- Prescribed by or in consultation with an allergist/immunologist or otolaryngologist
PA required for Dupixent in COPD with chronic bronchitis
Prior authorization is required for Dupixent for COPD with chronic bronchitis for reauthorization; approval requires documentation of blood eosinophil count, exacerbation history despite triple inhaled therapy, specialist prescriber, and clinical improvement.
- Prescribed by a pulmonologist
- Blood eosinophil count ≥150 cells/mcL within past 3 months
- History of ≥2 moderate or ≥1 severe COPD exacerbation in last year despite LABA+LAMA+ICS
- Reauthorization approval length: 12 months
PA required for Dupixent in EoE and prurigo nodularis
Prior authorization is required for Dupixent for eosinophilic esophagitis (EoE) and prurigo nodularis (PN); approvals require specialist prescribing and diagnostic confirmation specific to each condition.
- EoE: prescribed by a gastroenterologist and diagnosis confirmed by imaging (initial approval 6 months; reauth 12 months)
- PN: age-based criteria and required prior therapy trials (initial approval 6 months)
AFRS step therapy: intranasal corticosteroid trials required
For Allergic Fungal Rhinosinusitis (AFRS), approval requires failure of (or contraindication to) two intranasal corticosteroids prior to Dupixent.
- Examples: fluticasone, budesonide
Atopic dermatitis step therapy: topical then systemic options
For atopic dermatitis, prior authorization requires failure of topical steroid and nonsteroid topical therapy; alternatively, failure of two systemic/other options (e.g., an oral DMARD such as methotrexate or cyclosporine, or phototherapy) is required for certain pathways.
- Pediatric/adult pathways specify combination topical failure or two systemic/other therapy failures
- Dupixent dosing: every other week
CRSwNP step therapy: intranasal corticosteroids, Sinuva, and surgical history required
For chronic rhinosinusitis with nasal polyps (CRSwNP), approval requires failure of at least two intranasal corticosteroids and Sinuva, evidence of recurrent polyps/surgery, and adherence to nasal corticosteroid therapy.
- Prescribed by an allergist or ENT
- Recurrent nasal polyps after multiple prior sinus surgeries within past 2 years
- Member must be adherent to nasal corticosteroid
CSU step therapy: required sequence of antihistamines, montelukast, H2/hydroxyzine, and Xolair
For chronic spontaneous urticaria (CSU), approval requires documented failure of at least two second‑generation antihistamines, a high‑dose antihistamine trial, montelukast, either hydroxyzine or an H2 antagonist, and prior omalizumab (Xolair) with pre‑approval.
- Examples: loratadine, cetirizine (two second‑generation antihistamines)
- High‑dose trial example: cetirizine 20 mg daily
- H2 antagonists examples: famotidine, cimetidine
- Xolair (omalizumab) must have been tried with pre‑approval
Required prior therapy sequence for CSU before Dupixent
Before Dupixent for CSU, the patient must have failed an ordered sequence of therapies: two second‑generation antihistamines, a higher‑than‑normal dose antihistamine trial, montelukast, hydroxyzine or an H2 antagonist, and prior trial of omalizumab (Xolair) with pre‑approval.
- Failure of all listed therapies is required for initial authorization
- Initial approval length: 6 months
AFRS documentation: CT confirmation + two supportive findings and surgery history
For AFRS, documentation must include CT-confirmed diagnosis plus two supportive findings (such as IgE‑mediated response to fungal hyphae, positive fungal‑specific IgE, or positive fungal stain) and a history of sinonasal surgery.
- Supportive findings examples: IgE mediated inflammatory response to fungal hyphae; sensitization by skin testing; positive fungal‑specific IgE in serum; positive fungal stain of nasal contents
- Documented history of sinonasal surgery (e.g., functional endoscopic sinus surgery)
Asthma documentation: phenotype, eosinophil count, exacerbations, and controller trials
For asthma, documentation must show the prescribing pulmonologist confirms severe or eosinophilic phenotype, a history of frequent exacerbations, an eosinophil count ≥150/mcL within the past 6 months, and prior controller therapy trials (high‑dose ICS/LABA plus additional controllers).
- Prescribed by a pulmonologist
- Eosinophil count ≥150/mcL within past 6 months
- Prior treatment with high‑dose inhaled corticosteroid + LABA, leukotriene inhibitor, and LAMA
Bullous pemphigoid documentation: biopsy and prior immunosuppressant/corticosteroid trials
For bullous pemphigoid, documentation must include a biopsy‑confirmed diagnosis and evidence of failure of (or contraindication to) listed immunosuppressants (azathioprine, methotrexate, mycophenolate) and failure of oral corticosteroids.
- Prescribed by a dermatologist
- Histopathologic (biopsy) diagnosis required
- Failure of a 3‑month trial of azathioprine, methotrexate, or mycophenolate or contraindication to all
Required documentation for CSU: duration, severity, age, specialist, and prior therapies
For CSU initial authorization, document disease duration (≥6 weeks), severity (wheal count and impact on sleep/activities), age (≥12 years), specialist involvement, and all required prior medication trials including omalizumab pre‑approval.
- Diagnosis: hives and/or angioedema ≥6 weeks
- Severity: ≥50 wheals or large confluent wheals and itching impacting sleep or daily activities
- Prescribed by or in consultation with an allergist/immunologist or otolaryngologist
- Prior therapies: two second‑generation antihistamines; high‑dose antihistamine; montelukast; hydroxyzine or H2 antagonist; Xolair with pre‑approval
Required documentation for COPD: recent BEC, exacerbation history, and pulmonologist prescriber
For COPD reauthorization, document a recent blood eosinophil count (within 3 months) ≥150 cells/mcL, history of exacerbations despite adherence to triple inhaled therapy (LABA+LAMA+ICS), and that the prescriber is a pulmonologist.
- Blood eosinophil count ≥150 cells/mcL within past 3 months
- History of ≥2 moderate or ≥1 severe COPD exacerbation in last year despite adherence to inhaled LABA+LAMA+ICS
- Prescribed by a pulmonologist
Required documentation for EoE: diagnostic confirmation and gastroenterologist prescriber
For eosinophilic esophagitis (EoE), document diagnosis confirmation by endoscopy/biopsy or imaging and that the prescriber is a gastroenterologist.
- Prescribed by a gastroenterologist
- Diagnosis of eosinophilic esophagitis confirmed by imaging (e.g., endoscopy/biopsy as indicated in policy)
Denial risk: missing AFRS diagnostic confirmation
AFRS requests lacking CT confirmation plus two supportive findings (and surgery history) may be denied for failure to meet diagnostic confirmation requirements.
- Required supportive findings examples: fungal‑specific IgE, positive fungal stain, skin testing, IgE‑mediated response
Denial risk: missing asthma phenotype testing or controller therapy history
For asthma, absence of a documented eosinophil count ≥150/mcL within the past 6 months, lack of prior controller therapy documentation, or missing exacerbation history may trigger denial.
- Eosinophil threshold: ≥150/mcL within past 6 months
- Prior controller therapies required: high‑dose ICS/LABA plus leukotriene inhibitor and LAMA
- Evidence of frequent exacerbations (urgent care/ED visits or hospitalization) required
Denial risk: missing required prior therapies for CSU
Failure to document required prior trials for CSU—such as two second‑generation antihistamines, a high‑dose antihistamine trial, and montelukast—may result in denial of Dupixent.
- Required prior therapies include: two second‑generation antihistamines; antihistamine at higher‑than‑normal dose (e.g., cetirizine 20 mg); montelukast; hydroxyzine or H2 antagonist; prior Xolair (omalizumab) with pre‑approval
Denial risk: COPD eligibility not documented (BEC or exacerbation history)
For the COPD indication, lack of documentation of a blood eosinophil count ≥150 cells/mcL within the past 3 months or insufficient exacerbation history (at least 2 moderate or 1 severe in the past year despite LABA+LAMA+ICS) may lead to denial.
- BEC threshold: ≥150 cells/mcL within past 3 months
- Exacerbation history required: ≥2 moderate or ≥1 severe in last year despite adherence to triple inhaled therapy
Background
Dupilumab is an interleukin‑4/interleukin‑13 pathway–targeting monoclonal antibody indicated for multiple allergic and inflammatory conditions. This policy defines indication‑specific authorization and reauthorization requirements — including diagnostic confirmation, documented trials of prior therapies, specialist prescriber requirements, age and laboratory thresholds, and evidence of clinical improvement — that must be met for coverage of Dupixent.
Definitions and Clinical Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.